The daxxify® Difference

The First and Only
Peptide-Powered
Neuromodulator1-6

Our unique peptide formulation powers the benefits of the DAXXIFY® Difference—Fast, Lasts, and the Look.7-9*

*Onset as early as day 1, typically within 2 days. Based on pooled patient diary data from SAKURA 1 and SAKURA 2. At least 50% of patients in SAKURA 1 and SAKURA 2 had none or mild frown lines for 24 weeks (6 months) and 23.9 weeks (6 months) or longer, respectively, per both investigator’s and patient’s assessments. 64% of patients achieved an improvement in the appearance of skin texture at week 2 from a post hoc analysis of a Phase 2 clinical study with 60 patients.1,7-10

Seal Time Best Inventions 2023

Fast, Lasts and the Look:
The DAXXIFY® Difference

FAST

Onset as early as day 1 and typically within 2 days.7*

LASTS

Long lasting with gradual softening over time.8†

THE LOOK

Improvement in the appearance of skin texture and smooths even the deepest lines.8,9,11,12

*Based on pooled patient diary data from SAKURA 1 and SAKURA 2.1,7,8
†Median time to return to baseline wrinkle severity was 27.7 weeks in clinical studies.10

64% of patients achieved improvement in the appearance of skin texture at week 2
from a post hoc analysis of a Phase 2 clinical study with 60 patients.9

“The reaction that my patients have to the fact that [the appearance of] their skin texture is improved, and the fact that they're getting a long-lasting product, has made it an elevated experience for my patients.”

– Board Certified Dermatologist

Results may vary.

94% of patients preferred DAXXIFY® over their previous frown line treatment at week 2.13*

*Based on a survey of 149 patients at week 2.

Become a Daxxify® Provider

*Required.

By subscribing, you agree to receive updates from Revance Therapeutics, Inc. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, please review our Privacy Policy

There is award winning, and then there is multiple-cross-category award winning

The effects of DAXXIFY and all botulinum toxin products may spread from the area of injection to produce symptoms consistent with botulinum toxin effects. These symptoms have been reported hours to weeks after injection. Swallowing and breathing difficulties can be life threatening and there have been reports of death. DAXXIFY® is not approved for the treatment of spasticity or any conditions other than glabellar lines.

INDICATION DAXXIFY® (daxibotulinumtoxinA-Ianm) injection is an acetylcholine release inhibitor and neuromuscular blocking agent indicated for the temporary improvement in the appearance of moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity in adult patients.

IMPORTANT SAFETY INFORMATION

Contraindications
DAXXIFY® contraindications include hypersensitivity to any botulinum toxin preparation or any of the components in the formulation and infection at the injection site(s).

Warnings and Precautions
Please refer to Boxed Warning for Distant Spread of Toxin Effect.

The potency Units of DAXXIFY® are not interchangeable with other preparations of other botulinum toxin products. Recommended dose and frequency of administration should not be exceeded. Patients should seek immediate medical attention if respiratory, speech or swallowing difficulties occur. Use caution when administering to patients with pre-existing cardiovascular disease. Concomitant neuromuscular disorders may exacerbate clinical effects of treatment.

Adverse Reactions
The most commonly observed adverse reactions (≥1%) were headache (6%), eyelid ptosis (2%) and facial paresis (1%).

Drug Interactions
Co-administration of DAXXIFY® and aminoglycoside antibiotics, anticholinergic agents or any other agents interfering with neuromuscular transmission or muscle relaxants should only be performed with caution as the effect of DAXXIFY® may be potentiated. The effect of administering different botulinum neurotoxins during course of treatment with DAXXIFY® is unknown.

Use in Specific Populations
DAXXIFY® is not recommended for use in children or pregnant women.

Please see DAXXIFY® full Prescribing Information, including Boxed Warning and Medication Guide.

DAXI-001720.2

REFERENCES

  • DAXXIFY®. Prescribing Information. Revance Therapeutics, Inc; 2023.
  • Fabi SG, Cohen JL, Green LJ, et al. DaxibotulinumtoxinA for Injection for the treatment of glabellar lines: efficacy results from SAKURA 3, a large, open-label, phase 3 safety study. Dermatol Surg. 2020;47(1):48-54.
  • BOTOX® Cosmetic. Prescribing Information. Allergan Inc; 2023.
  • XEOMIN®. Prescribing Information. Merz Pharmaceuticals GmbH; 2024.
  • DYSPORT®. Prescribing Information. Ipsen Biopharmaceuticals Ltd; 2023.
  • JEUVEAU®. Prescribing Information. Evolus, Inc; 2020.
  • Data on File. D220801001. Newark, CA: Revance Therapeutics, Inc, 2021.
  • Bertucci V, Solish N, Kaufman-Janette J, et al. DaxibotulinumtoxinA for Injection has a prolonged duration of response in the treatment of glabellar lines: pooled data from two multicenter, randomized, double-blind, placebo-controlled, phase 3 studies (SAKURA 1 and SAKURA 2). J Am Acad Dermatol. 2020;82(4):838-845.
  • Data on File. D231201010. Newark, CA: Revance Therapeutics, Inc, 2023.
  • Carruthers JD, Fagien S, Joseph JH, et al. DaxibotulinumtoxinA for Injection for the treatment of glabellar lines: results from each of two multicenter, randomized, double-blind, placebo-controlled, phase 3 studies (SAKURA 1 and SAKURA 2). Plast Reconstr Surg. 2020;145(1):45-58.
  • Data on File. Gross. American Academy of Dermatology. Newark, CA: Revance Therapeutics, Inc, 2021.
  • Brown J, Stephenson J, Kooken K, Sparrow J. Impact of DaxibotulinumtoxinA for Injection on skin smoothness following treatment of glabellar lines. Poster presented at: Derm2023 NP/PA CME Conference; August 3-6, 2023; Las Vegas, NV.
  • Data on File. DAXXIFY® Patient Survey. Newark, CA: Revance Therapeutics, Inc; 2022.